Treprostinil palmitil inhalation powder (TPIP) is an investigational once-daily inhaled prodrug formulation under development for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Phase 2b data in PAH reported significant efficacy outcomes, and phase 3 planning was initiated. It is not approved in any jurisdiction.
Insmed reported total revenues of $606.4 million for 2025, with ARIKAYCE growing 19% annually. The FDA granted orphan drug designation to treprostinil palmitil for pulmonary arterial hypertension treatment in January 2026.
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07481981 |
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07234032 |
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07179380 |
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) |
RECRUITING | PHASE3 |
| NCT06091579 |
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants |
COMPLETED | PHASE1 |
| NCT05649722 |
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) |
COMPLETED | PHASE2/PHASE3 |
